Myozyme package insert
WebThe recommended dosage of Lumizyme ® (alglucosidase alfa) is 20 mg per kg of body weight, administered every two weeks as an intravenous infusion. The total volume of … WebFULL PRESCRIBING INFORMATION SPRYCEL® (dasatinib) 1 INDICATIONS AND USAGE SPRYCEL® (dasatinib) is indicated for the treatment of adult patients with • newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid
Myozyme package insert
Did you know?
Web1 APPROVED PACKAGE INSERT FOR MOZOBIL® SCHEDULING STATUS: S4 PROPRIETARY NAME (AND DOSAGE FORM): MOZOBIL® (solution for injection) COMPOSITION: Active ingredient: Each 1,2 ml vial contains 24,0 mg plerixafor (20 mg/ml). Inactive ingredients: Sodium chloride, hydrochloric acid, sodium hydroxide, water for injection. Each ml … WebApr 4, 2024 · Myozyme is indicated for long-term enzyme-replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid-α-glucosidase deficiency). In …
WebOct 11, 2012 · Although enzyme replacement therapy with alglucosidase alfa (Myozyme) in Pompe disease has improved the prognosis of this otherwise lethal disorder, patients who develop high sustained antibody... WebJun 25, 2013 · Patients received alglucosidase alfa (Myozyme®/Lumizyme®) manufactured by Genzyme Corporation (Cambridge, MA) at cumulative doses of 20 mg/kg, administered by infusion every other week based on Myozyme® package insert, or weekly, based on clinical judgment of the treating physicians.
WebMyozyme . alglucosidase alfa . This is a summary of the European public assessment report (EPAR) for Myozyme. ... For the full list of all side effects reported with Myozyme, see the package leaflet. Myozyme EMA/58201/2014 Page 3/3 Patients who receive Myozyme may develop antibodies (proteins that are produced in response to ... WebThis package insert is continually updated: Please read carefully before using a new pack. MYOZYME® Alglucosidase alfa for Injection (r-DNA origin) Lyophilized Powder for concentrate for solution for Intravenous infusion 1. NAME OF THE MEDICINAL PRODUCT Myozyme® (alglucosidase alfa) 50 mg lyophilized powder for concentrate for solution for
Web4 4.4 Special warnings and precautions for use Tremor Approximately 37% of patients in clinical trialsin type 1 Gaucher disease, and 58% of patients in a
Web• NEXVIAZYME is administered as intravenous infusion. For patients weighing: o ≥30 kg, the recommended dosage is 20 mg/kg (of actual body weight) every two weeks [see Dosage … how to maintain vinyl windowsWebJan 19, 2024 · 1 Indications and Usage 2 Dosage and Administration 3 Dosage Forms and Strengths 4 Contraindictions 5 Warnings and Precautions 6 Adverse Reactions 7 Drug Interactions 8 Use in Specific Populations... journal of nursing \u0026 healthcareWebFDA-approved indication: Myozyme (alglucosidase alfa) is a lysosomal glycogen-specific enzyme indicated for use in patients with Pompe disease (GAA deficiency). Myozyme … journal of nursing management官网WebLUMIZYME (alglucosidase alfa) [see Description (11)] is a lysosomal glycogen-specific enzyme indicated for patients 8 years and older with late (non-infantile) onset Pompe … journal of nursing regulation 2022WebMyozyme is provided as a lyophilized powder for solution for injection. The finished product is provided in a 20 mL vial containing 52.5 mg alglucosidase alfa, 210 mg mannitol, 0.5 mg polysorbate 80, 9.9 mg sodium phosphate dibasic heptahydrate and 31.2 mg sodium phosphate monobasic how to maintain water qualityWebNov 1, 2024 · Package insert / product label Generic name: diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed Dosage form: injection, suspension Drug class: Vaccine combinations Medically … journal of nurse managementWebfull prescribing information warning: risk of anaphylaxis, hypersensitivity and immune-mediated reactions, and risk of cardiorespiratory failure journal of nursing science update